Pathology of the lung in surfactant-treated neonates.
Respiratory distress syndrome (RDS) is associated with prematurity-related deficiency of surfactant. Surfactant replacement therapy has been used in premature infants to prevent RDS or reduce its severity. In this study we describe the pathology of the lungs after surfactant replacement therapy. All the neonatal autopsies during the years 1989 and 1990 (n = 235) were examined. Infants > or = 31 weeks gestation, with congenital anomalies or who lived more than 2 weeks were excluded from the study. Infants who had received intratracheal Survanta, a modified surfactant extracted from cow lung (n = 14), were compared with infants who did not receive exogenous surfactant (n = 20). The two groups were statistically comparable in terms of weight, gestational and postnatal age, gender, and clinical management. H&E-stained lung sections were examined independently by two pathologists without knowledge of surfactant treatment status; any discrepancies in histological evaluation were resolved by joint review. Nine histological features were evaluated including hyaline membranes, necrosis of the epithelium, hemorrhage, edema, inflammation, metaplasia, arteriolar muscular hyperplasia, interstitial fibrosis, and pulmonary interstitial emphysema (PIE). Histological changes were graded from 0 to 3+. When it was present, cerebral periventricular-intraventricular hemorrhage (PVH-IVH) was graded 1-4. The presence or absence of sepsis and necrotizing enterocolitis (NEC) were also determined. Comparisons between patient groups were performed using the Mann-Whitney U, Student's t and chi 2 tests. The severity of hyaline membrane disease, PIE, and epithelial necrosis was less severe in the surfactant-treated group than in the untreated group. There were no differences between the two groups in the degree of pulmonary hemorrhage or in the incidence of PVH-IVH, sepsis, or NEC.
Pinar
H
H
Department of Pathology and Laboratory Medicine, Women and Infants' Hospital of Rhode Island, Providence 02905.
Makarova
N
N
Rubin
L P
LP
Singer
D B
DB
D001688:Biological Products; D004305:Dose-Response Relationship, Drug; D004761:Enterocolitis, Pseudomembranous / Q000473:pathology; D006801:Humans; D006819:Hyaline Membrane Disease / Q000473:pathology; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects / Q000473:pathology*; D009336:Necrosis / Q000473:pathology; D011656:Pulmonary Emphysema / Q000473:pathology; D011663:Pulmonary Surfactants / Q000494:pharmacology*; D012127:Respiratory Distress Syndrome, Newborn / Q000473:pathology; D018805:Sepsis / Q000473:pathology; D012720:Severity of Illness Index
D001688:Biological Products; D011663:Pulmonary Surfactants; C072197:beractant